China Resources Pharmaceutical Group Ltd
HKEX:3320
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.51
6.99
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Pharmaceutical Group Ltd
Total Current Assets
China Resources Pharmaceutical Group Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Total Current Assets
HK$197.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Total Current Assets
HK$8.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Total Current Assets
HK$5.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Total Current Assets
ÂĄ15.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Total Current Assets
ÂĄ25.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
||
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Total Current Assets
$1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
27%
|
China Resources Pharmaceutical Group Ltd
Glance View
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The firm mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
See Also
What is China Resources Pharmaceutical Group Ltd's Total Current Assets?
Total Current Assets
197.6B
HKD
Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Total Current Assets amounts to 197.6B HKD.
What is China Resources Pharmaceutical Group Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
7%
Over the last year, the Total Current Assets growth was 9%. The average annual Total Current Assets growth rates for China Resources Pharmaceutical Group Ltd have been 5% over the past three years , 7% over the past five years .